Skip to main content

Table 5 Poisson multivariate regression model for number of flares during follow-up of 12 months by sex

From: Gout treatment and comorbidities: a retrospective cohort study in a large US managed care population

   Females (N = 43,304) Males (N = 134,333)
   IRR 95% CI p-value IRR 95% CI p-value
Age < 50 1.00 (ref.)   1.00 (ref.)  
  50 - 59 1.66 (1.49, 1.85) < .0001 0.83 (0.80, 0.85) < .0001
  60 - 69 1.93 (1.73, 2.16) < .0001 0.76 (0.73, 0.79) < .0001
  70 - 79 1.69 (1.51, 1.90) < .0001 0.56 (0.53, 0.60) < .0001
  80 - 89 1.31 (1.12, 1.52) 0.001 0.53 (0.48, 0.59) < .0001
Comorbidities:        
Cardiometabolic*   1.60 (1.48, 1.74) < .0001 1.10 (1.06, 1.13) < .0001
Diabetes   1.48 (1.35, 1.63) < .0001 0.97 (0.93, 1.02) 0.262
Gastrointestinal   0.86 (0.78, 0.96) 0.005 1.07 (1.02, 1.13) 0.011
Hematological   1.03 (0.88, 1.20) 0.720 0.94 (0.84, 1.06) 0.340
Myopathy   1.21 (0.50, 2.91) 0.670 0.84 (0.50, 1.42) 0.509
Osteoporosis   0.88 (0.78, 1.00) 0.044 1.11 (0.99, 1.25) 0.076
  1. IRR = Incidence rate ratio.
  2. * Cardiometabolic disease include congestive heart failure, ischaemic heart disease, hypertension, cerebrovascular disease, peripheral arterial disease, dyslipidemia.